KA/EN
Register
Medicines reference
Search
Search
Product

Canigen CHPPi/L

Favourites

Canine distemper virus + Canine adenovirus + Canine parvovirus + Canine parainfluenza virus + Leptospira canicola + Leptospira icterohaemorrhagiae · Virbac

1 form: suspension. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Form Species Dose Frequency Georgia
Suspension · Dog Dog 1 ml
Reconstitute the lyophilisate with the liquid component and inject one 1 ml dose subcutaneously immediately. Give the first dose from 8 weeks and the second 3-4 weeks later. When maternal antibodies may interfere, a third dose from 15 weeks is recommended. Give one dose one year after the primary series; thereafter CDV/CAV/CPV revaccination may be up to every 3 years, while CPiV and Leptospira require annual boosters. Vaccinate healthy animals only. Do not use during pregnancy or lactation. Hypersensitivity, including anaphylaxis, requires immediate symptomatic treatment.
 · primary series, then component-specific revaccination		 primary series, then component-specific revaccination Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: კანიგენი CHPPi/L
№ 1-03/154; 102-11; 247-11
Verified on: 23 Oct 2026
Details: pack, label wording, sources, registration

Canigen CHPPi/L, Suspension

lyophilisate and suspension for injection, 1 ml dose for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.1/10
Very good
vetman assessment

Canigen CHPPi/L

lyophilisate and suspension for injection, 1 ml dose for dogs
Assessed clinical scopeDog · Complete dog label from 8 weeks: component-specific prevention/reduction of death, disease, infection, shedding and renal colonisation/lesions from CDV, CAV-1/2, CPV-2b/2c, CPiV and L. Canicola/Icterohaemorrhagiae · Subcutaneous
Care settingPreventive veterinary vaccination after clinical assessment, with documented cold chain, age/risk schedule, batch and emergency readiness
vetman score 8.1/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 1-03/154; 102-11; 247-11 · Verified on 23 Oct 2026

A well-documented, challenge-supported core-plus-CPiV/bivalent-leptospira vaccine with exact Georgian/EU authorisation and an aligned GB lineage. It is very good when its component-specific claims and schedule fit the patient, but it is not a universal maximum-coverage programme: modern puppy timing and local need for broader leptospiral serogroups remain decisive.

Regulatory and scientific credibility9.0/10

The exact product has three current Georgian registrations, a valid multi-country EU authorisation, current detailed product information and a public quality/safety/efficacy assessment. GB authorises the aligned Virbac lineage as Canixin; exact US APHIS licensure is absent.

Clinical efficacy7.5/10

Exact challenge and duration studies support the component-specific claims and three-year core protection after the annual booster. Value is reduced by narrower two-serogroup leptospiral coverage, annual CPiV/leptospiral need, small long-duration groups, an antibody-based CAV-2 endpoint and the need to align the puppy endpoint with maternal-antibody guidance.

Safety and tolerability8.0/10

The exact dossier, field use and overdose studies support a favourable benefit-risk in healthy dogs. Common local swelling/lethargy and rare systemic events are usually transient, but very rare anaphylaxis, no pregnancy/lactation data, unknown concomitant-medicine safety and live-strain shedding require controls.

Clinical practicality7.5/10

One fixed 1 ml SC dose is efficient and the core interval becomes up to three years after the annual booster. Two or sometimes three puppy visits, annual CPiV/Leptospira, product selection in broader-leptospira regions, strict cold chain, paired-vial reconstitution and immediate use create continuing clinic workload.

Full-course cost-effectiveness-

Current Georgian per-course price was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Complete component-specific scope: the vaccine prevents some endpoints and only reduces others. Do not promise sterile immunity, prevention of every respiratory syndrome, every parvovirus infection or leptospirosis outside the included Canicola/Icterohaemorrhagiae serogroups.
  • Primary schedule: give one 1 ml SC dose from 8 weeks and repeat after 3-4 weeks. Maternal antibody may interfere; when relevant add a third dose from 15 weeks and fit the final core dose to current guidance of at least 16 weeks or later in higher-risk settings.
  • Onset is component-specific after the primary course: 3 weeks for CDV/CAV-2/CPV, 4 weeks for CAV-1/CPiV, 5 weeks for Canicola and 2 weeks for Icterohaemorrhagiae. Protection is not immediate; manage exposure before onset.
  • Duration/schedule: all components have one-year duration after the primary course. Give a full booster at one year; thereafter core CDV/CAV/CPV intervals may be up to 3 years, but CPiV and Leptospira require an appropriate annual booster.
  • Leptospira boundary: this is a bivalent Canicola/Icterohaemorrhagiae product. Compare local epidemiology and current four-serovar options; it does not establish protection against Australis, Grippotyphosa, Pomona or every circulating strain.
  • Vaccinate healthy dogs only. Defer and assess fever, substantial illness, incubating infection, marked malnutrition/parasitism or immunosuppression; vaccination neither treats existing disease nor replaces isolation, sanitation and outbreak control.
  • Common transient swelling/oedema up to 4 cm and lethargy can occur; rare pain/pruritus, fever, anorexia, vomiting or diarrhoea are labelled. Very rare anaphylaxis/allergic skin reactions require immediate treatment and adverse-event reporting.
  • Do not use during pregnancy or lactation. Concomitant-medicine safety/efficacy is not established: decide before/after timing case by case and never mix with another veterinary medicine. Live CAV-2/CPV strains may shed without demonstrated contact-animal pathogenicity.
  • Handling: reconstitute the complete lyophilisate with its full liquid fraction, shake gently and inject 1 ml SC immediately. Maintain 2-8 C transport/storage, protect from light, do not freeze, verify vial/lot/expiry and discard unused reconstituted material.
  • Record the exact product, batch, route, date and next component-specific due date. Accidental human self-injection needs prompt medical advice with the label. For travel/boarding, verify jurisdictional documentation and required vaccine components rather than assuming this product covers rabies or every mandate.
Assessment sources
  1. Canigen CHPPi/L GE register2026
  2. EU UPD Canigen CHPPi/L2026
  3. Canigen CHPPi/L assessment2026
  4. Canixin aligned GB record2026
  5. WSAVA vaccination 20242024
  6. AAHA canine vaccination 20222022
  7. ACVIM leptospirosis consensus 20232023
  8. Leptospirosis vaccine meta-analysis2022
  9. USDA veterinary biologics catalogue2026
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Canine distemper virus3 log10 CCID50/dose Canine adenovirus4 log10 CCID50/dose Canine parvovirus5 log10 CCID50/dose Canine parainfluenza virus5 log10 CCID50/dose Leptospira canicola4350 ELISA units/dose Leptospira icterohaemorrhagiae4250 ELISA units/dose
Formulation Type
Suspension
Administration route
Subcutaneous
Manufacturer
Virbac · France
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: კანიგენი CHPPi/L
№ 1-03/154; 102-11; 247-11
Verified on: 23 Oct 2026
 EU Yes, veterinary
№ FR/V/0237/001
Verified on: 23 Oct 2026
 UK Yes, veterinary
№ Vm 05653/5054
Verified on: 23 Oct 2026
 US No
Verified on: 23 Oct 2026
Controlled in Georgia
Unknown
Information not fully verified Dog-only SC vaccine for component-specific CDV, CAV-1/2, CPV-2b/2c, CPiV and Canicola/Icterohaemorrhagiae leptospirosis endpoints. Reconstitute with the full liquid fraction and inject 1 ml immediately. Start from 8 weeks, repeat in 3-4 weeks and add a third dose from 15 weeks when maternal antibody may interfere; fit the final core dose to current age/risk guidance. Booster at one year, then core viruses up to q3y while CPiV/Leptospira remain annual.
DoseSpeciesWeightRouteFrequencySource
1 ml
Reconstitute the lyophilisate with the liquid component and inject one 1 ml dose subcutaneously immediately. Give the first dose from 8 weeks and the second 3-4 weeks later. When maternal antibodies may interfere, a third dose from 15 weeks is recommended. Give one dose one year after the primary series; thereafter CDV/CAV/CPV revaccination may be up to every 3 years, while CPiV and Leptospira require annual boosters. Vaccinate healthy animals only. Do not use during pregnancy or lactation. Hypersensitivity, including anaphylaxis, requires immediate symptomatic treatment.
 Dog Any weight Subcutaneous primary series, then component-specific revaccination
EU UPD Canigen CHPPi/L
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Canigen CHPPi/L - official product information
EU Union Product Database, 2026

Canine distemper virus: No dose supported by a publicly verifiable source yet

Canine adenovirus: No dose supported by a publicly verifiable source yet

Canine parvovirus: No dose supported by a publicly verifiable source yet

Canine parainfluenza virus: No dose supported by a publicly verifiable source yet

Leptospira canicola: No dose supported by a publicly verifiable source yet

Leptospira icterohaemorrhagiae: No dose supported by a publicly verifiable source yet

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗